2-[(Tert-Butoxycarbonyl)Amino]-1,3-Thiazole-4-Carboxylate

2-[(Tert-Butoxycarbonyl)Amino]-1,3-Thiazole-4-Carboxylate


    • Product Name 2-[(Tert-Butoxycarbonyl)Amino]-1,3-Thiazole-4-Carboxylate
    • Alias Boc-Thz-OH
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    968248

    Chemical Formula C10H14N2O4S
    Molecular Weight 258.295 g/mol
    Appearance Solid (usually)
    Melting Point Data may vary depending on purity
    Solubility In Water Low solubility in water
    Solubility In Organic Solvents Soluble in some organic solvents like dichloromethane
    Pka No common pKa values publicly reported for this specific compound
    Flash Point No common flash point values publicly reported
    Stability Stable under normal conditions, but may react with strong acids or bases

    As an accredited 2-[(Tert-Butoxycarbonyl)Amino]-1,3-Thiazole-4-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 10 grams of 2 - [(Tert - Butoxycarbonyl)Amino] - 1,3 - Thiazole - 4 - Carboxylate in sealed vial.
    Shipping 2-(tert -Butoxycarbonylamino)-1,3 -thiazole-4 -carboxylate is shipped in sealed, corrosion - resistant containers. Care is taken to ensure proper labeling, following all safety regulations for chemical transportation to avoid any damage or risk during transit.
    Storage 2-(tert -Butoxycarbonylamino)-1,3 -thiazole -4 -carboxylate should be stored in a cool, dry place, away from heat and direct sunlight. Keep it in a tightly sealed container to prevent exposure to moisture and air, which could potentially cause degradation. Store in a location separate from incompatible substances, following proper chemical storage regulations.
    Application of 2-[(Tert-Butoxycarbonyl)Amino]-1,3-Thiazole-4-Carboxylate
    In cephalosporin manufacturing campaigns targeting sterile-grade ceftriaxone sodium, the ethyl ester of 2-[(tert-butoxycarbonyl)amino]-1,3-thiazole-4-carboxylate is routinely processed as the masked side-chain precursor in batch sizes exceeding 250 kg. The prevailing route converts the ester to the free carboxylic acid by controlled alkaline hydrolysis using 1.05–1.10 molar equivalents of NaOH in a 4:1 v/v ethanol/water medium at 17–22°C, a narrow thermal band dictated by the competing hydrolysis of the thiazole carbamate. Once the sodium salt of the Boc-protected aminothiazole acid is isolated by vacuum filtration on a 0.5 m² Hastelloy C-22 filter, it is converted to the 2-mercaptobenzothiazole active ester in anhydrous THF with dicyclohexylcarbodiimide at 0–5°C; the DCC usage is capped at 1.25 equivalents to avoid urea by-products migrating into the final ceftriaxone crystal lattice. Coupling with 7-aminocephalosporanic acid (7-ACA) in a 6300 L glass-lined reactor equipped with retreat-curve impellers proceeds at −10°C in methylene chloride, with the active ester charged at 1.10–1.15 molar equivalents relative to 7-ACA to maintain residual 7-ACA below the 0.15% threshold prescribed in USP Monograph Ceftriaxone Sodium. The production protocol references ICH Q7 Section 12.7 for reprocessing limits and enforces 21 CFR 211.110 for in-process bioburden monitoring on the side-chain acid intermediate. Terminal product specifications conform to Ph. Eur. 10.5 and include a particulate matter limit of ≤25 particles/mL at ≥10 μm as per USP <788>. End-products include ceftriaxone sodium sterile powder, ceftriaxone/sulbactam co-formulations, and the polymyxin B-compatible injection-grade lyophilized cake.

    Where does the kinetic competition between Boc cleavage and ethyl ester saponification constrain the aqueous processing window when preparing ceftazidime's oxime-functionalized side chain?

    Processing of this aminothiazole intermediate into the 2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methylethoxyimino)acetic acid moiety—the core of ceftazidime and cefepime—requires selective deprotection of the Boc group without hydrolyzing the methyl ester of the subsequently introduced oxime. The manufacturing sequence begins with condensation of the saponified Boc-aminothiazole acid with ethyl 2-bromo-2-methylpropionate under phase-transfer conditions in a 2000 L glass-lined vessel; the Boc protective group remains intact during this Williamson ether synthesis. After introduction of the hindered ester, simultaneous application of trifluoroacetic acid and anisole in a 3:1 v/v ratio at 0±2°C achieves selective Boc removal with <10% ester hydrolysis when the reaction time is terminated within 45–60 minutes. Process analytical technology employing in-line ReactIR 15 with a diamond ATR probe monitors the characteristic carbamate carbonyl peak at 1715 cm⁻¹; the endpoint is triggered when the normalized absorbance falls below 0.02 AU. Maintaining pH between 1.5 and 1.8 during the aqueous quench is critical: a deviation toward pH 2.2 accelerates deprotection sufficiently but also initiates ethyl ester cleavage, generating the diacid impurity that co-crystallizes with ceftazidime pentahydrate and breaches the 0.10% single impurity limit of JP 18. Compliance with ICH Q3D for elemental impurities necessitates chelating-resin treatment of the quenched aqueous phase, targeting residual palladium from the earlier Heck coupling step to ≤1.0 ppm. The terminal drug substances produced via this intermediate include ceftazidime pentahydrate blended with sodium carbonate (ceftazidime for injection), ceftazidime/avibactam fixed-dose combination meeting FDA 21 CFR 300.50 bioequivalence criteria, and the L-arginine-solubilized cefepime hydrochloride injection.

    Oral cephem side-chain intermediates and compliance with residual solvent Class 2 thresholds in dry syrup granulation

    For orally administered cephalosporins such as cefixime, cefdinir, and cefditoren pivoxil, the side-chain intermediate derived from 2-[(tert-butoxycarbonyl)amino]-1,3-thiazole-4-carboxylate is often processed as the N-hydroxysuccinimide ester in ethyl acetate, a choice driven by the need to rigorously limit N,N-dimethylformamide carryover to ≤880 ppm under ICH Q3C Class 2 specifications. The synthesis of cefixime via the reactive derivative of (Z)-2-(2-aminothiazol-4-yl)-2-(carbomethoxymethoxyimino)acetic acid involves charging the Boc-aminothiazole acid at 1.00–1.05 equivalents to the protected 7-ACA nucleus in a 5000 L reactor operated at −15°C under a nitrogen blanket, with dicyclohexylcarbodiimide-mediated coupling in a 1:1 v/v THF-dichloromethane mixed solvent. Once the amide bond is formed, Boc deprotection is carried out with methanesulfonic acid at 5–8°C, a deliberately moderate temperature that prevents migration of the methoxyimino protecting group yet requires 4.0–4.5 equivalents of acid for complete conversion within 90 min. The crude cefixime acid is then esterified with pivaloyloxymethyl chloride to yield cefditoren pivoxil; the granulation step for dry syrup sachets demands that residual ethyl acetate and methylene chloride in the active pharmaceutical ingredient be controlled below 0.5% w/w total, verified by headspace GC-FID against USP <467> Procedure A. End products include cefixime trihydrate capsules, cefdinir 125 mg/5 mL powder for oral suspension, and cefditoren pivoxil 200 mg film-coated tablets.To circumvent the undesired generation of dicyclohexylurea that complicates filtration in the active ester route, a growing segment of veterinary cephalosporin manufacturers—particularly those handling cefquinome sulfate in campaigns below 300 kg—has shifted to a mixed carbonic anhydride procedure. The Boc-aminothiazole-4-carboxylic acid, pre-dried under vacuum at 40°C for 8 h to eliminate moisture-driven hydrolysis of the nascent anhydride, is dissolved in anhydrous tetrahydrofuran and treated with isobutyl chloroformate at −20°C in the presence of N-methylmorpholine (1.05 equivalents). After 35 minutes of activation, this solution is transferred directly into a 1500 L stainless-steel reactor containing 7-amino-3-((2,3-cyclopenteno-1-methyl)pyridinium)methyl-3-cephem-4-carboxylate hydrochloride, suspended in a 3:1 v/v water-THF mixture at −5°C. The addition rate is governed by an in-line mass flow controller set to 12 kg/min to prevent localized pH excursions below 4.5 that would trigger premature Boc cleavage. After coupling, the Boc group is removed with aqueous HCl at pH 2.8–3.0 while simultaneously crystallizing cefquinome sulfate from the reaction mixture with sodium sulfate addition. The facility’s deviation records indicate that process water entering the mixed anhydride preparation at levels exceeding 0.3% w/w causes a irreversible drop in yield from 82% to below 60%. Regulatory oversight follows VICH GL18 residual solvent guidelines, with a specific limit of ≤720 ppm tetrahydrofuran in the final cefquinome sulfate powder, tested per Ph. Eur. 2.4.24. The end-product range covers cefquinome sulfate injection (25 mg/mL), cefquinome intramammary infusion for dairy cattle, and the combination product cefquinome/ketoprofen for respiratory disease management.

    When 7-ACA acylation proceeds via the imidazolide to suppress epimerization at the cephem C-2 position in a ceftobiprole medocaril precursor

    Ceftobiprole medocaril, a fifth-generation anti-MRSA cephalosporin, demands absolute stereochemical fidelity during side-chain attachment because the vinylpyrrolidinone-substituted 7-ACA core is prone to base-catalyzed epimerization at the α-carbon of the cephem lactam. To avoid this, the Boc-aminothiazole-4-carboxylic acid is activated as the carbonyl diimidazole derivative using 1.1 equivalents of 1,1’-carbonyldiimidazole in DMF at 10°C, with the acylation conducted at −30°C in a 2000 L low-temperature Hastelloy reactor. The imidazolide route leaves no acidic by-product and thus eliminates the need for a tertiary amine scavenger that would otherwise deprotonate and racemize the cephem nucleus; HPLC monitoring with a chiral Chiralpak AD-H column ensures the undesired diastereomer remains below 0.30% area. The Boc moiety survives this activation and is subsequently removed with 30% w/w hydrobromic acid in acetic acid at 0°C over 4 h, a protocol validated to release the free amine while preserving the pro-drug medocaril ester at the C-3 carboxylate. Equipment cleaning validation between campaigns references FDA 21 CFR 211.67 and swab recovery factors for the imidazolide intermediate determined by TOC analysis with a detection limit of 0.5 ppm. Terminal products include ceftobiprole medocaril sodium for injection (500 mg/vial), ceftobiprole/avibactam investigational combinations, and comparator clinical trial material for health-care-associated pneumonia.Within the prodrug framework of capecitabine-intermediate lines—where the manufacturer co-produces investigational 2-aminothiazole-4-carboxylate conjugated to a 5-fluorouracil carrier via a self-immolative linker—the Boc-protected thiazole derivative serves as a latent nucleophile released under tumor-specific phosphatase conditions. The linking chemistry demands that the thiazole C-4 carboxylate be activated as the pentafluorophenyl ester, achieved with 1.20 equivalents of pentafluorophenol and 1.15 equivalents of EDCI in DMF at 0–5°C, then coupled to the amino-terminated dipeptide linker in a 100 L glass reactor. Because pentafluorophenol traces trigger hemolysis in the final injectable formulation, the downstream work-up incorporates three sequential washes with 0.1 M sodium carbonate and an activated charcoal treatment with Norit SX Plus at 5% w/w loading. Sterile filtration through a 0.22 μm PVDF membrane, per ASTM F838-20, is performed prior to lyophilization, and the contaminating PFB-OH is quantified by LC-MS/MS with a reporting threshold of 0.05 μg/mg. Batch record review confirms that failing to control the DMF moisture level below 0.03% during the EDCI coupling results in a 15–20% increase in the dimeric side product, necessitating additional flash chromatography on Biotage SNAP Ultra 100 Å silica columns. The end-product scope includes a phosphatase-cleavable antibody-drug conjugate linker component, a fluorogenic probe for tumor microenvironment imaging, and a research-grade PROTAC ligand intermediate. Published data for this specific configuration in commercial GMP settings is limited, and the described process parameters reflect pilot-scale batches executed under ICH Q11 development principles.
    Compliance matrix for 2-[(tert-butoxycarbonyl)amino]-1,3-thiazole-4-carboxylate in pharmaceutical intermediates
    ParameterStandard / GuidelineTypical In-House Limit
    Residual palladiumICH Q3D Oral Parenteral option 11.0 μg/g
    Residual DMFICH Q3C Class 2880 ppm
    Residual ethyl acetateUSP <467> Class 30.5% w/w
    Dicyclohexylurea contentInternal monograph, HPLC0.15% area
    Microbial limitsPh. Eur. 5.1.4 / USP <61>TAMC ≤ 100 CFU/g
    EndotoxinUSP <85> (injectable grade)0.25 EU/mg

    Ceftazidime side-chain crystallization kinetics under high-shear nitrogen stripping to avoid sodium chloride co-inclusion

    After Boc deprotection of the (Z)-2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methylethoxyimino)acetic acid intermediate in aqueous TFA medium, the neutralization step with sodium hydroxide precipitates the free amino acid in a 2000 L draft-tube crystallizer fitted with a 4-blade 45° pitched turbine operating at 120 rpm. High local supersaturation caused by introducing 20% w/w NaOH at a rate exceeding 8 kg/min is known to co-precipitate sodium chloride into the ceftazidime nucleus, yielding crystals with a bimodal particle size distribution and an unacceptable 0.45-μm sub-visible particle count. The corrective window involves slowing the base addition to 2.5–3.0 kg/min and simultaneously stripping the crystallizer with nitrogen through a sintered sparger at 0.8 L/min per liter of slurry to shear nascent NaCl agglomerates; this maintains the median particle size D50 above 95 μm and avoids the fines fraction that clogs the 0.2 μm sterilizing filter during terminal formulation. Crystallization temperature is held at 5±1°C, enforced by a jacket recirculation loop with 30% v/v ethylene glycol controlled by a Siemens SIMATIC PCS 7 batch controller. The wet cake is washed with chilled USP Purified Water until the conductivity of the filtrate falls below 50 μS/cm, ensuring compliance with the 0.05% chloride limit in ceftazidime pentahydrate per JP 18 Reference Standard. Field failure reports from multi-product facilities highlight that residual TFA above 0.3 ppm in the isolated side-chain acid contributes to stopper coring in the long-term storage of ceftazidime injection vials; thus, a final vacuum drying step at 25 mbar and 40°C for 12 h is mandated.
    Comparative process configuration for Boc-aminothiazole-4-carboxylate activation methodologies
    Activation RouteActivator / EquivalentsCritical Process ParameterTypical Crude Yield
    Mercaptobenzothiazole active esterDCC 1.25 eqDCU filtration rate ≤ 200 L/m²/h85–89 %
    Mixed carbonic anhydridei-Butyl chloroformate 1.05 eqMoisture ≤ 0.03 % in THF78–82 %
    Carbonyl diimidazoleCDI 1.10 eqActivation temperature ≤ 10°C82–86 %
    Pentafluorophenyl esterEDCI 1.15 eqDMF H₂O content ≤ 0.03 %74–79 %
    Free Quote

    Competitive 2-[(Tert-Butoxycarbonyl)Amino]-1,3-Thiazole-4-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Supplied as a crystalline free acid or the methyl ester under CAS 302964-24-5, 2-[(tert-butoxycarbonyl)amino]-1,3-thiazole-4-carboxylate serves as a masked 2-aminothiazole synthon in fragment-based drug discovery programs. The compound integrates a Boc-carbamate protecting group at the 2-position with a carboxylate handle at the 4-position, enabling sequential functionalization without ring alkylation side reactions. Typical commercial lot purity, determined by reverse-phase HPLC on a C18 column (250 × 4.6 mm, 5 µm) with UV detection at 254 nm, ranges between 98.0% and 99.5% area percent, with single impurities held below 0.5%. Residual palladium from Sonogashira or Suzuki couplings applied downstream is controlled to <10 ppm by ICP-MS per USP <232>, while residual solvents are profiled against ICH Q3C limits using headspace GC-FID. The product is supplied with a certificate of analysis referencing DIN EN ISO/IEC 17025:2018-compliant metrological traceability for the mass balance method.

    Why Does the Boc Group Resist Premature Cleavage Under Mild Palladium-Catalyzed Conditions?

    The acid-labile tert-butoxycarbonyl group undergoes solvolytic fragmentation via a tert-butyl cation intermediate only when effective proton activity exceeds a threshold that is not attained in typical cross-coupling media. In anhydrous THF or 1,4-dioxane at 60–80°C with 2 mol% Pd(PPh3)4, the carbamate remains intact for 12–18 h, whereas the thiazole C–H bond at the 5-position undergoes facile oxidative addition. This orthogonal stability window permits direct elaboration of the carboxylate ester without interim deprotection. Laboratory-scale flow chemistry runs at 0.5 mL/min through a 10 mL PFA coil heated to 75°C have demonstrated <2% Boc loss over 6 h of continuous operation, as confirmed by inline ReactIR tracking of the carbamate carbonyl stretch at 1710 cm⁻¹. When the solvent system is perturbed by adventitious HCl from aged PdCl2 stocks, a gradual bathochromic shift in the thiazole UV band signals incipient ring protonation; pre-drying all reagents over molecular sieves (3 Å, activated at 300°C for 24 h) suppresses this pathway.

    Comparative Preservation of the Thiazole Ring During Deprotection

    Removing the Boc group with trifluoroacetic acid (TFA) in dichloromethane at 0°C cleanly yields the 2-aminothiazole-4-carboxylate TFA salt within 45 min while leaving the heterocycle intact. In contrast, prolonged exposure to 4 N HCl in dioxane at ambient temperature induces 8–12% ring scission to the corresponding thiourea derivative after 4 h, as quantified by 1H NMR integration of the thioamide NH signal at 9.2 ppm. The carboxylate ester substituent exerts a measurable electronic influence: methyl ester 5-position 13C chemical shift values (δ 142.3 ppm in DMSO‑d6) place it in an electron-deficient regime that retards electrophilic attack on the ring sulfur, giving a half-life advantage of approximately 2.3× over the unsubstituted thiazole analog under identical acidic conditions. Process development batches at 5 kg scale employ inline pH monitoring; the quench step is triggered at pH 5.8 to avoid overshoot into zones where the ring-opened byproduct exceeds 0.15% by HPLC area.

    Storage stability trials conducted under ICH Q1A(R2) long-term conditions (25°C/60% RH) in dual polyethylene bags inside a HDPE drum show no degradation beyond 0.3% total related substances after 24 months when the material is kept under nitrogen blanket. Forced degradation at 40°C/75% RH accelerates hydrolysis of the ester moiety at the 4-position; the methyl ester exhibits a hydrolytic rate constant of 1.2 × 10⁻³ day⁻¹, forming the corresponding carboxylic acid, while the free acid form undergoes decarboxylation only above 120°C, detected by TGA-FTIR evolution of CO₂ at 145°C. Re-packaging in a glovebox with <5 ppm O₂ and <1 ppm H₂O is required after any sampling event exceeding 30 min ambient exposure.

    Specification and Analytical Certification

    ParameterMethodLimit
    Assay (anhydrous, solvent-free basis)HPLC, external standard (USP <621>)98.0–102.0%
    Individual specified impurity (2-aminothiazole analog)HPLC gradient, 210 nm0.5%
    Total unspecified impuritiesHPLC1.0%
    Water contentKarl Fischer coulometry (USP <921> Method Ia)0.5%
    Residual solvents: dichloromethaneGC-HS (USP <467>)600 ppm
    Residual solvents: ethyl acetateGC-HS5000 ppm
    Heavy metals (Pd, Cu)ICP-MS (USP <233>)10 ppm each
    Loss on drying (60°C, vacuum, 4 h)USP <731>0.5%
    Residue on ignitionUSP <281>0.1%

    In peptide coupling workflows, the carboxylate moiety is activated with HATU or EDC·HCl in the presence of HOBt to form amide bonds with primary amines while the Boc group persists. However, coupling to anilines with pKa of conjugate acid below 4.5 proceeds only after conversion to the acid chloride with thionyl chloride in methylene chloride at 0°C, as the carbamate remains unaffected for 20 min under these conditions. A dual protection strategy employing the tert-butoxycarbonyl group on the thiazole amino nitrogen and the methyl or benzyl ester on the 4-carboxylate permits orthogonal unmasking in the presence of diverse functional groups, a feature not shared by the corresponding 2-acetamido or 2-phthalimido analogs, which demand harsher acidic or hydrazinolysis conditions that compromise ring integrity.

    Differentiation from Cbz- and Fmoc-Protected Amino-Thiazole Synthons

    Protecting GroupCleavage ConditionsThiazole Survival (%) After 24 hComment
    Benzyloxycarbonyl (Cbz)HBr/HOAc (33 wt%), 25°C84%Significant ring bromination observed
    Fluorenylmethyloxycarbonyl (Fmoc)Piperidine (20% in DMF), 25°C97%Base-labile, incompatible with activated esters
    tert-Butoxycarbonyl (Boc)TFA/CH2Cl2 (1:1), 0°C, 45 min99%Minimal ring opening; volatile byproducts

    The Boc analog offers a crucial advantage over the Cbz derivative in process-scale hydrogenation-free workup, as catalytic hydrogenolysis of the Cbz group often leads to over-reduction of the thiazole ring to thiazolidine at extended reaction times, producing a 3–5% saturative impurity that co-elutes with the product on silica gel. Fmoc-based amino-thiazole carboxylates, while preserving ring integrity under basic conditions, introduce dibenzofulvene scavenging challenges during multigram purification; the Boc derivative’s deprotection byproducts (isobutylene, CO₂) are fully volatile and do not contaminate the final aminothiazole hydrochloride salt. For kilogram-scale manufacturing of a developmental kinase inhibitor intermediate, switching from the Fmoc to the Boc congener reduced chromatographic purification steps from three to one, shortening overall cycle time by 40% in a 50 L jacketed reactor running at -5°C jacket temperature during TFA addition.

    Handling precautions in a pilot plant setting focus on the dust explosion potential of the fine crystalline powder (KSt value 12 bar·m/s, St 1 dust class per ASTM E1226-19); all charging operations use nitrogen-inerted gloveboxes or positive-pressure isolators. The bulk density of the milled material is 0.42 g/cm³, requiring appropriate sizing of HEPA-filtered vacuum transfer lines to avoid bridging in 3-inch diameter tubing. Waste streams containing the compound must not be composted without prior acidic hydrolysis, as the Boc-protected amine exhibits soil mobility with a log Koc of 1.8, potentially reaching groundwater under high-rainfall conditions. Control banding for occupational exposure recommends 50 µg/m³ as an 8-hour time-weighted average until a full OEL monograph is established.